Inventor · disambiguated record
Andreas Loew
Also filed as: LOEW ANDREAS
59 granted patents·54 pending applications·606 citations·filing 2002–2025
98Inventor score
Files withNOVARTIS AG38MARENGO THERAPEUTICS INC35LOEW ANDREAS8THOMSON LICENSING8ELSTAR THERAPEUTICS INC5
Top patents by PatentIndex Score
113 records- 0197US9815901B2Treatment of cancer using a CD123 chimeric antigen receptorBROGDON JENNIFER·Filed 2015·Granted Nov 14, 2017·94 cites·40 claims
- 0297US9573988B2Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cellsBROGDON JENNIFER·Filed 2014·Granted Feb 21, 2017·87 cites·94 claims
- 0396US11291721B2Multispecific and multifunctional molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2017·Granted Apr 5, 2022·15 cites·22 claims
- 0496US10253086B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2016·Granted Apr 9, 2019·37 cites·35 claims
- 0596US9394368B2Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptorBROGDON JENNIFER·Filed 2014·Granted Jul 19, 2016·112 cites·38 claims
- 0695US11965025B2Method of treating solid cancers with bispecific interleukin-anti-TCRß moleculesMARENGO THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·7 cites·26 claims
- 0795US10927184B2Treatment of cancer using humanized anti-CD19 chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Feb 23, 2021·10 cites·26 claims
- 0895US10221245B2Treatment of cancer using humanized anti-CD19 chimeric antigen receptorNOVARTIS AG·Filed 2014·Granted Mar 5, 2019·36 cites·67 claims
- 0994US11149076B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2019·Granted Oct 19, 2021·9 cites·32 claims
- 1094US10287354B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2014·Granted May 14, 2019·29 cites·63 claims
- 1193US11845797B2Anti-TCR antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2019·Granted Dec 19, 2023·7 cites·34 claims
- 1293US10640569B2Human mesothelin chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2014·Granted May 5, 2020·15 cites·49 claims
- 1393US9023791B2Fibroblast growth factor 21 mutationsBOETTCHER BRIAN R·Filed 2011·Granted May 5, 2015·37 cites·39 claims
- 1492US12351632B2Anti-TCR antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2023·Granted Jul 8, 2025·1 cites·33 claims
- 1592US10577417B2Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapyNOVARTIS AG·Filed 2015·Granted Mar 3, 2020·10 cites·33 claims
- 1691US12486326B2Anti-TCR antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2023·Granted Dec 2, 2025·1 cites·10 claims
- 1791US12286477B2Anti-TCR antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2022·Granted Apr 29, 2025·1 cites·29 claims
- 1891US11028177B2Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cellsNOVARTIS AG·Filed 2017·Granted Jun 8, 2021·4 cites·47 claims
- 1989US12344657B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2021·Granted Jul 1, 2025·1 cites·27 claims
- 2089US10308717B2Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptorNOVARTIS AG·Filed 2016·Granted Jun 4, 2019·4 cites·9 claims
- 2188US11865167B2Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptorNOVARTIS AG·Filed 2019·Granted Jan 9, 2024·2 cites·39 claims
- 2288US10669323B2Methods of treating metabolic disorders with dual function fibroblast growth factor 21 proteinsBOETTCHER BRIAN R·Filed 2016·Granted Jun 2, 2020·5 cites·15 claims
- 2388US9458214B2Dual function fibroblast growth factor 21 proteinsNOVARTIS AG·Filed 2012·Granted Oct 4, 2016·15 cites·16 claims
- 2488US9290573B2Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodiesCONG FENG·Filed 2011·Granted Mar 22, 2016·16 cites·9 claims
- 2587US8883735B2Low density lipoprotein-related protein 6 (LRP6)-half life extender constructsNOVARTIS AG·Filed 2012·Granted Nov 11, 2014·8 cites·34 claims
- 2686US2024301060A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2785US2025011461A1Human mesothelin chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 2884US12152073B2Multifunctional molecules that bind to calreticulin and uses thereofMARENGO THERAPEUTICS INC·Filed 2019·Granted Nov 26, 2024·4 cites·20 claims
- 2983US12384842B2Antibody molecules that bind to NKP30 and uses thereofMARENGO THERAPEUTICS INC·Filed 2021·Granted Aug 12, 2025·1 cites·23 claims
- 3083US11578130B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Feb 14, 2023·1 cites·30 claims
- 3183US10703819B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Jul 7, 2020·1 cites·33 claims
- 3282US2025340640A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3382US2024294662A1Human mesothelin chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 3480US12247060B2Calreticulin binding constructs and engineered T cells for the treatment of diseasesMARENGO THERAPEUTICS INC·Filed 2019·Granted Mar 11, 2025·1 cites·24 claims
- 3580US2023374105A1Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)-expressing cellNOVARTIS AG·Filed 2023·Application pending·0 cites
- 3679US11542488B2Sortase synthesized chimeric antigen receptorsNOVARTIS AG·Filed 2015·Granted Jan 3, 2023·2 cites·14 claims
- 3779US2023220090A1Treatment of cancer using a cd123 chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 3878US2025215085A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3978US2024317850A1Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapyNOVARTIS AG·Filed 2024·Application pending·0 cites
- 4077US9173960B2Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructsNOVARTIS AG·Filed 2014·Granted Nov 3, 2015·2 cites·30 claims
- 4177US2022064297A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4275US9512199B2Fibronectin cradle molecules and libraries thereofLOEW ANDREAS·Filed 2011·Granted Dec 6, 2016·3 cites·5 claims
- 4374US11673971B2Multispecific antibody molecules comprising lambda and kappa light chainsMARENGO THERAPEUTICS INC·Filed 2017·Granted Jun 13, 2023·1 cites·10 claims
- 4474US2025074998A1Multifunctional molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4572US12421323B2Multispecific antibody molecules comprising lambda and kappa light chainsMARENGO THERAPEUTICS INC·Filed 2023·Granted Sep 23, 2025·0 cites·13 claims
- 4672US2023026049A1Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 4770US11591404B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Feb 28, 2023·0 cites·33 claims
- 4870US2020283729A1Treatment of cancer using chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4970US2023227552A1Anti-tcr antibody molecules and uses thereofMARENGO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 5069US2022378833A1Dimerization switches and uses thereofNOVARTIS AG·Filed 2022·Application pending·0 cites
Showing the top 50 of 113 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Andreas Loew files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →